Phase 3 ASCEND Study of Pirfenidone in Idiopathic Pulmonary Fibrosis Presented at American Thoracic Society (ATS) and Published in New England Journal of Medicine

- Investor Conference Call and Webcast Today at 8 p.m. EDT (5 p.m. PDT) -

BRISBANE, Calif., May 18, 2014  - InterMune, Inc. (NASDAQ:ITMN ) today reported that results from the Phase 3 ASCEND study evaluating pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) were presented today at the International Conference of the American Thoracic Society (ATS) in San Diego, and published on-line in the New England Journal of Medicine. Dr. Talmadge King, Professor and Chair, Department of Medicine, University of California, San Francisco and Co-chair of the ASCEND protocol steering committee, presented the ASCEND results.

In ASCEND, pirfenidone significantly reduced decline in lung function as measured by change in percent predicted forced vital capacity (FVC) from Baseline to Week 52 (rank ANCOVA p

Clovis Oncology Announces Clinical Data to Be Presented at 2014 ASCO Annual Meeting

Abstracts provide updates on the Company’s three investigational therapies in development:

- CO-1686, an oral, novel mutant EGFR inhibitor for non-small cell lung cancer (NSCLC)
- Rucaparib, an oral PARP inhibitor for ovarian cancer, and
- Lucitanib, an oral tyrosine-kinase inhibitor for breast cancer and squamous NSCLC

BOULDER, Colo.- Clovis Oncology (CLVS) announced that five abstracts highlighting clinical progress and results from Phase 1 and 2 studies of the company’s three compounds will be presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Bristol-Myers Squibb and Celldex Therapeutics Announce Clinical Trial Collaboration to Evaluate the Combination of Investigational Immunotherapies Nivolumab and Varlilumab

NEW YORK & HAMPTON, N.J.-- Bristol-Myers Squibb Company (BMY) and Celldex Therapeutics, Inc. (CLDX) announced today that they have entered into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of nivolumab, Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, and varlilumab, Celldex’s CD27 targeting investigational antibody in a Phase 1/2 study. Multiple tumor types will be explored in the study, which could potentially include non-small cell lung cancer (NSCLC), metastatic melanoma, ovarian, colorectal (CRC) and squamous cell head and neck cancers.

Halozyme Reports First Quarter 2014 Financial Results

bPositive top-line data from studies with HTI-501 in cellulite and Hylenex with insulin pumps

SAN DIEGO, May 12, 2014 -- Halozyme Therapeutics, Inc. (HALO) today reported financial results for the first quarter ended March 31, 2014. Financial highlights for the first quarter include revenues of $12.0 million and a net loss of $26.5 million, or $0.22 per share. This compares to revenues of $11.8 million and a net loss of $19.3 million, or $0.17 per share, for the first quarter of 2013.  The increase in net loss reflects Halozyme's increased investment in clinical trials for its PEGPH20 and Hylenex^® proprietary programs.